Last reviewed · How we verify
Amlodipine plus Losartan
Amlodipine and losartan work together to lower blood pressure by relaxing blood vessels through calcium channel blockade and angiotensin II receptor antagonism.
Amlodipine and losartan work together to lower blood pressure by relaxing blood vessels through calcium channel blockade and angiotensin II receptor antagonism. Used for Hypertension.
At a glance
| Generic name | Amlodipine plus Losartan |
|---|---|
| Also known as | Amosartan |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Calcium channel blocker + Angiotensin II receptor blocker combination |
| Target | L-type calcium channels; AT1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Losartan is an angiotensin II receptor blocker (ARB) that blocks AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release. The combination provides complementary antihypertensive effects through two distinct mechanisms.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
- Cough
Key clinical trials
- Hypertension in Young Adults Trial (PHASE2)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) (PHASE3)
- Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design (NA)
- Arterial Stiffness and Blood Pressure (NA)
- Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED) (PHASE4)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine plus Losartan CI brief — competitive landscape report
- Amlodipine plus Losartan updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI